Navigation Links
EUSA Pharma Out-Licenses Preclinical-Stage Human Antibody to GlaxoSmithKline for up to $44 Million Plus Royalties
Date:2/18/2008

Out-Licensing Enhances EUSA's Strategic Focus on Late-Stage and Marketed

Products

DOYLESTOWN, Pennsylvania and OXFORD, England, February 18 /PRNewswire/ -- EUSA Pharma Inc ('EUSA'), a transatlantic specialty pharmaceutical company focused on oncology, pain control and critical care, today announced that it has out-licensed the exclusive world-wide rights to its preclinical-stage human anti-interleukin-6 antibody to GlaxoSmithKline (GSK) for a consideration of up to $44 million, comprising an upfront fee and development milestones, plus royalties on future sales. As part of the agreement EUSA will pay approximately 50% of the overall consideration to its development partner for the antibody, Vaccinex Inc. GSK will fund and conduct all future development, production and commercialization of the product.

Interleukin-6 is a pro-inflammatory cytokine and B-cell growth factor and acts as a resistance factor to standard chemotherapy. EUSA's product, OP-R003, is the first fully human anti-interleukin-6 antibody, with target indications in oncology and inflammatory diseases. OP-R003 is derived from a first generation murine antibody, elsilimomab, which has achieved promising clinical results as a lymphoma therapy. As a fully human antibody, OP-R003 has the potential to offer improved tolerability and a superior safety profile.

EUSA acquired OP-R003 as part of the company's 2007 acquisition of OPi SA. OPi had previously entered a collaboration with Vaccinex, a specialist antibody discovery and development company, to optimize and develop OP-R003 as a therapy for rheumatoid arthritis and lymphoma.

"The out-licensing of this early-stage antibody is another strategic milestone for EUSA, as we continue to focus our business on marketed and late-stage products in the oncology, pain control and critical care areas," said Bryan Morton, Chief Executive of EUSA Pharma.

Commenting on the acquisition, Brian McVe
'/>"/>

SOURCE EUSA Pharma Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... Maureen Salamon HealthDay ... Black women undergoing in vitro fertilization (IVF) are only about ... the popular assisted reproduction technique, new research indicates, and the ... In the study, about 31 percent of white patients became ... patients. Analyzing more than 4,000 IVF cycles over two ...
(Date:10/22/2014)... Maureen Salamon HealthDay ... A crucial part of conventional in vitro fertilization (IVF) -- ... instead take place in a device inside the vagina, new ... contend that the device, called an INVOcell, might sharply cut ... also make the technology more accessible to those who don,t ...
(Date:10/22/2014)... By Dennis Thompson HealthDay ... freelance cameraman who was diagnosed with Ebola while working for ... system and can leave the special isolation unit at Nebraska Medical ... two weeks, the hospital said Tuesday. A blood test confirmed ... Ashoka Mukpo, 33, can head home to Providence, R.I., NBC ...
(Date:10/20/2014)... 2014 Allegheny General Hospital’s (AGH) Cardiovascular ... physicians to repair a damaged mitral valve as the ... system, developed by Abbott Vascular , is designed ... life-threatening condition in which the heart’s mitral valve leaflets ... from the heart’s left ventricle into the left atrium. ...
(Date:10/20/2014)... Women’s health specialist, Dr. Amber Murphy, MD, Ob/Gyn ... Inc., A Division of MaternOhio Clinical Associates, Inc., who ... patients annually. Dr. Murphy will provide a full range ... women’s life. She is accepting new patients at two ... , Dr. Murphy offers a wide variety of services ...
Breaking Medicine News(10 mins):Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 2Health News:U.S. Cameraman Treated for Ebola 'Free' of the Virus 3Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 2Health News:Allegheny General Hospital Introduces New, Beating-Heart Procedure for Mitral Valve Repair 3Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 2Health News:OhioHealth Welcomes New Women’s Health Specialist to MaternOhio Specialists in Obstetrics & Gynecology of Columbus, Inc. 3
... the first half of Craneware,s 10th Anniversary YearATLANTA, Feb. 25 ... for hospitals and health systems, is pleased to announce its interim ... , ... contributing to: , ...
... just received a letter and information indicating that all ... have been added to a list maintained under a ... will analyze the letter and other information fully and ... it has no evidence the drugs on the market ...
... Hall to be Board Chairman; Siegrist Takes on Executive PostSOUTH ... announced his decision to transition from president and chief executive ... Inc., effective March 16. Rick Siegrist, M.B.A., president of a ... member of the Press Ganey Board of Directors, will take ...
... to Chair Advisory CouncilHARRISBURG, Pa., Feb. 25 ... from the field to the dinner table, Governor Edward ... Governor,s Food Safety Council and announced his appointees to ... on food safety, members will advise the Governor on ...
... Department of Labor,s Occupational Safety and Health Administration (OSHA) ... doing business as Ro-Corp Inc., for alleged willful, repeat ... more than $1.2 million in penalties for numerous violations ... company,s facility in East St. Louis.OSHA began an inspection ...
... Church of Scientology Volunteer Ministers of Melbourne, Australia ... wildfires that took an estimated 200 lives. , ... ... Scientology Volunteer Ministers , a grassroots community service organization, ...
Cached Medicine News:Health News:Craneware Announces Half-Year Results 2Health News:Press Statement Issued by Ranbaxy Laboratories Limited 2Health News:Changing of the Guard at Press Ganey 2Health News:Changing of the Guard at Press Ganey 3Health News:Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply 2Health News:Governor Rendell Forms Food Safety Council to Protect Public Health, Food Supply 3Health News:U.S. Department of Labor's OSHA proposes more than $1.2 million penalty to St. Louis area chemical repackaging and distribution company 2Health News:Scientology Volunteer Ministers Provide Disaster Relief During Melbourne Fires 2
(Date:10/22/2014)... , Oct. 22, 2014  Charlene Vernak, RPh, of ... , recently was awarded the George Roentsch Scholarship ... received the award in Houston ... scholarship is awarded annually to an independent pharmacist and ... of George Roentsch , a well-known pharmacist in ...
(Date:10/22/2014)... , Oct. 22, 2014 Moms are ... health trackers for themselves and their kids, according to ... Report: Health & Fitness Go Mobile for Moms, the ... Series. BabyCenter, the number 1 pregnancy and parenting web ... that 55 percent of moms surveyed say they can,t ...
(Date:10/22/2014)... SAN DIEGO , Oct. 22, 2014 ... II medical device received 510 (k) OTC clearance by ... the AVACEN 100 to be marketed over the Internet ... with arthritis; muscle spasms; and minor strains and sprains ... The AVACEN 100 (MSRP $2495) is a ...
Breaking Medicine Technology:PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 2BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 3BabyCenter Finds Mom Ready to Live the "Measured Life" in its U.S. Mobile Mom 2014 Report: Health & Fitness Go Mobile for Moms 4AVACEN Medical Announces FDA Clearance of First Medical Device with Internal Game Mode 2
...  Leading events organiser UBM Live has revealed further ... Pharma Portfolio, CPhI Southeast Asia (SEA) 2012. Set to debut ... Indonesia, CPhI SEA is the first trade show and exhibition ... sector in the ASEAN region. CPhI SEA ...
... Conn., April 18, 2012   A new retrospective ... rates of intracranial hemorrhage (ICH), including both fatal and ... taken twice daily compared with warfarin. Results of the ... Journal of the American Heart Association. ...
Cached Medicine Technology:Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 2New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 3New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 4New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 5New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 6New Sub-Analysis Evaluates Outcomes Associated with Lower Intracranial Hemorrhage Rates for Pradaxa® (dabigatran etexilate mesylate) Versus Warfarin in the RE-LY® Trial 7
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
The Natural-Hip combines the surgical simplicity of a straight stem with many of the best features of an anatomic stem....
Classic proven design with superior clinical results...
...
Medicine Products: